RxDoctor Payments Data

Ted Schoettinger, MD

Family Medicine · Maineville, OHNPI 1972582799

Payments from drug & device makers

$697in general payments, 2019–2025

Across 52 payments — averaging $13.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$166
  • Sumitomo Pharma America, Inc.$138
  • Johnson & Johnson$131
  • Lilly USA, LLC$74
  • AstraZeneca$51
  • Novo Nordisk$48
  • plus $88 from 2 others

What the payments were for

  • Food & beverage$67897%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$697 in reported general payments places this provider in the 55th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$187,752
Medicare patients
276
Services billed
1,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$147,280
MounjaroTirzepatide106$135,068
JardianceEmpagliflozin76$93,997
EliquisApixaban94$89,338
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog41$64,618
TrulicityDulaglutide37$50,271
FarxigaDapagliflozin Propanediol32$46,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$42,363
VascepaIcosapent Ethyl45$27,126
Tresiba Flextouch U-200Insulin Degludec13$24,442
XareltoRivaroxaban17$19,076
JanuviaSitagliptin Phosphate11$17,537
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$16,850
Spiriva RespimatTiotropium Bromide15$9,737
Felbamate12$7,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$74$185,339143 claims
Novo NordiskOzempic, Novolog$48$151,214107 claims
AstraZenecaFarxiga, Breztri Aerosphere$51$63,14153 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$45$49,45066 claims
Johnson & JohnsonXarelto$131$19,07617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Maineville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →